EP
STOK icon

Eversept Partners’s Stoke Therapeutics STOK Stock Holding History

Eversept Partners’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-52,006
Closed -$639K – 78
2024
Q3 		$639K Sell
52,006
-9,271
-15% -$131K 0.04% 65
2024
Q2 		$828K Sell
61,277
-228,723
-79% -$3.09M 0.06% 71
2024
Q1 		$3.92M Buy
+290,000
New +$1.76M 0.26% 51

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Eversept Partners's STOK Position: Q4 2024 in Review

Eversept Partners sold out of Stoke Therapeutics (STOK) in Q4 2024, closing a stake of 52,006 shares — an estimated $639K sold.

Eversept Partners first reported a position in STOK in Q1 2024 and held it in 3 quarters. The position peaked at $3.92M in Q1 2024. 130 funds tracked by Wall St. Rank hold STOK as of Q4 2024.

  • Eversept Partners reported no remaining Stoke Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Eversept Partners sold 52,006 Stoke Therapeutics shares in Q4 2024, an estimated $639K.
  • Eversept Partners first reported a position in Stoke Therapeutics in Q1 2024 and held it in 3 quarters.
  • Eversept Partners's Stoke Therapeutics position peaked at $3.92M in Q1 2024.
  • 130 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2024.

Based on Eversept Partners's 13F filing for Q4 2024, filed 14 Feb 2025.